{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:57:57Z","timestamp":1794535077791,"version":"4.9.1"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"am","delay-in-days":298,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.psychres.2025.116446","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T03:32:39Z","timestamp":1742009559000},"page":"116446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies"],"prefix":"10.1016","volume":"348","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8071-7412","authenticated-orcid":false,"given":"Jeremy","family":"Weleff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7948-2050","authenticated-orcid":false,"given":"Alejandra","family":"Pulido-Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9998-8001","authenticated-orcid":false,"given":"Ardavan Mohammad","family":"Aghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2428-7793","authenticated-orcid":false,"given":"Kevin","family":"Ing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0193-318X","authenticated-orcid":false,"given":"Miranda","family":"Arakelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3513-1883","authenticated-orcid":false,"given":"Rodrigo","family":"Fontenele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8391-4785","authenticated-orcid":false,"given":"Neil","family":"Nero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8963-5701","authenticated-orcid":false,"given":"Brian S","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Bassir Nia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo A","family":"Angarita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2025.116446_bib0002","series-title":"Provisional Drug Overdose Death Counts","author":"Ahmad","year":"2021"},{"key":"10.1016\/j.psychres.2025.116446_bib0003","first-page":"577","article-title":"A systematic review of the cardiotoxicity of methadone","volume":"14","author":"Alinejad","year":"2015","journal-title":"Excli J."},{"issue":"3","key":"10.1016\/j.psychres.2025.116446_bib0004","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/105504999305848","article-title":"Treatment of acute opioid withdrawal with Ibogaine [https:\/\/doi.org\/10.1080\/105504999305848]","volume":"8","author":"Alper","year":"1999","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.psychres.2025.116446_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103518","article-title":"Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting","volume":"100","author":"Argento","year":"2022","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.psychres.2025.116446_bib0006","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/7854_2017_474","article-title":"Classic hallucinogens and mystical experiences: phenomenology and neural correlates","volume":"36","author":"Barrett","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"1","key":"10.1016\/j.psychres.2025.116446_bib0007","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","author":"Bell","year":"2020","journal-title":"Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2025.116446_bib0008","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1360-0443.2009.02627.x","article-title":"Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.psychres.2025.116446_bib0009","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.psychres.2025.116446_bib0010","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2025.116446_bib0011","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/00952990.2017.1320802","article-title":"Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes","volume":"44","author":"Brown","year":"2018","journal-title":"Am. J. Drug. Alcohol. Abuse"},{"issue":"6","key":"10.1016\/j.psychres.2025.116446_bib0012","doi-asserted-by":"crossref","first-page":"e13229","DOI":"10.1111\/adb.13229","article-title":"Classic psychedelics and alcohol use disorders: a systematic review of human and animal studies","volume":"27","author":"Calleja-Conde","year":"2022","journal-title":"Addict. Biol."},{"issue":"1","key":"10.1016\/j.psychres.2025.116446_bib0013","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0166-4328(94)90080-9","article-title":"The inhibitory effect of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine","volume":"65","author":"Cappendijk","year":"1994","journal-title":"Behav. Brain Res."},{"issue":"Suppl 1","key":"10.1016\/j.psychres.2025.116446_bib0014","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1111\/pme.12915","article-title":"Cardiac effects of opioid therapy","volume":"16","author":"Chen","year":"2015","journal-title":"Pain Med."},{"key":"10.1016\/j.psychres.2025.116446_bib0001","series-title":"Psychedelic Drugs: Considerations for Clinical Investigations Guidance for Industry DRAFT GUIDANCE","year":"2023"},{"issue":"2","key":"10.1016\/j.psychres.2025.116446_bib0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11845-015-1314-5","article-title":"Demographic and clinical factors predicting retention in methadone maintenance: results from an Irish cohort","volume":"185","author":"Darker","year":"2016","journal-title":"Ir. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.psychres.2025.116446_bib0016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1556\/2054.01.2017.009","article-title":"Subjective effectiveness of ibogaine treatment for problematic opioid consumption: short- and long-term outcomes and current psychological functioning","volume":"1","author":"Davis","year":"2017","journal-title":"J. Psychedel. Stud."},{"issue":"4","key":"10.1016\/j.psychres.2025.116446_bib0017","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/02791072.2018.1487607","article-title":"A mixed-method analysis of persisting effects associated with positive outcomes following ibogaine detoxification","volume":"50","author":"Davis","year":"2018","journal-title":"J. Psychoact. Drug."},{"issue":"3","key":"10.1016\/j.psychres.2025.116446_bib0018","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF02246099","article-title":"Effects of ibogaine on responding maintained by food, cocaine and heroin reinforcement in rats","volume":"117","author":"Dworkin","year":"1995","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.psychres.2025.116446_bib0019","first-page":"64","article-title":"Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats","volume":"294","author":"Dzoljic","year":"1988","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"issue":"8\u20139","key":"10.1016\/j.psychres.2025.116446_bib0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1472-8206.1992.tb00127.x","article-title":"Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice","volume":"6","author":"Franc\u00e9s","year":"1992","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.psychres.2025.116446_bib0021","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3389\/fpsyt.2019.00955","article-title":"Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey","volume":"10","author":"Garcia-Romeu","year":"2019","journal-title":"Front. Psychiatry"},{"issue":"9","key":"10.1016\/j.psychres.2025.116446_bib0022","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881119845793","article-title":"Cessation and reduction in alcohol consumption and misuse after psychedelic use","volume":"33","author":"Garcia-Romeu","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2025.116446_bib0023","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/ajad.12545","volume":"26","author":"Geoffroy","year":"2017","journal-title":"Am. J. Addict."},{"issue":"1\u20132","key":"10.1016\/j.psychres.2025.116446_bib0024","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0006-8993(94)90948-2","article-title":"Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum","volume":"657","author":"Glick","year":"1994","journal-title":"Brain Res."},{"issue":"5","key":"10.1016\/j.psychres.2025.116446_bib0025","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0028-3908(92)90089-8","article-title":"Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor","volume":"31","author":"Glick","year":"1992","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.psychres.2025.116446_bib0026","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0014-2999(91)90474-5","article-title":"Effects and aftereffects of ibogaine on morphine self-administration in rats","volume":"195","author":"Glick","year":"1991","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.psychres.2025.116446_bib0027","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/cpdd.254","article-title":"Ascending single-dose, double-blind, placebo-controlled safety study of Noribogaine in opioid-dependent patients","volume":"5","author":"Glue","year":"2016","journal-title":"Clin. Pharmacol. Drug. Dev."},{"issue":"10173","key":"10.1016\/j.psychres.2025.116446_bib0028","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.psychres.2025.116446_bib0029","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/ADM.0000000000000929","article-title":"Synergistic effect of ketamine and buprenorphine observed in the treatment of buprenorphine precipitated opioid withdrawal in a patient with fentanyl use","volume":"16","author":"Hailozian","year":"2022","journal-title":"J. Addict. Med."},{"issue":"1","key":"10.1016\/j.psychres.2025.116446_bib0030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.psychres.2025.116446_bib0031","unstructured":"Innovation, V.H. Covidence systematic review software. Veritas Health Innovation. Available at www.covidence.org."},{"issue":"11","key":"10.1016\/j.psychres.2025.116446_bib0032","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2025.116446_bib0033","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol. Abuse"},{"issue":"7","key":"10.1016\/j.psychres.2025.116446_bib0034","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0269881116684335","article-title":"An online survey of tobacco smoking cessation associated with naturalistic psychedelic use","volume":"31","author":"Johnson","year":"2017","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2025.116446_bib0035","doi-asserted-by":"crossref","first-page":"10578","DOI":"10.1038\/s41598-022-14809-3","article-title":"Associations between classic psychedelics and nicotine dependence in a nationally representative sample","volume":"12","author":"Jones","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.psychres.2025.116446_bib0036","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1038\/s41598-022-08085-4","article-title":"Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample","volume":"12","author":"Jones","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.psychres.2025.116446_bib0037","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1038\/s41598-022-06580-2","article-title":"Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study","volume":"12","author":"Jones","year":"2022","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.psychres.2025.116446_bib0038","doi-asserted-by":"crossref","first-page":"388","DOI":"10.15585\/mmwr.mm6817a3","article-title":"Drug overdose deaths involving cocaine and psychostimulants with abuse potential - United States, 2003-2017","volume":"68","author":"Kariisa","year":"2019","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"4","key":"10.1016\/j.psychres.2025.116446_bib0039","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1227\/neu.0000000000002275","article-title":"Psychedelic-assisted therapy and Psychedelic science: a review and perspective on opportunities in neurosurgery and neuro-oncology","volume":"92","author":"Kelly","year":"2023","journal-title":"Neurosurgery"},{"key":"10.1016\/j.psychres.2025.116446_bib0040","article-title":"What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size","volume":"3","author":"Keyes","year":"2022","journal-title":"Drug. Alcoh. Depend. Rep."},{"issue":"1","key":"10.1016\/j.psychres.2025.116446_bib0041","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/jamapsychiatry.2022.4020","article-title":"Clinical trial design challenges and opportunities for emerging treatments for opioid use disorder: a review","volume":"80","author":"Kiluk","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2025.116446_bib0042","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/JCP.0000000000000966","article-title":"Hallucinogen persisting perception disorder after Ibogaine treatment for opioid dependence","volume":"38","author":"Knuijver","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.psychres.2025.116446_bib0043","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/add.15448","article-title":"Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study","volume":"117","author":"Knuijver","year":"2022","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.psychres.2025.116446_bib0044","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.3390\/molecules20022208","article-title":"The anti-addiction drug ibogaine and the heart: a delicate relation","volume":"20","author":"Koenig","year":"2015","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.psychres.2025.116446_bib0045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0740-5472(02)00275-1","article-title":"Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up","volume":"23","author":"Krupitsky","year":"2002","journal-title":"J. Subst. Abuse Treat."},{"issue":"1","key":"10.1016\/j.psychres.2025.116446_bib0046","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/02791072.2007.10399860","article-title":"Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence","volume":"39","author":"Krupitsky","year":"2007","journal-title":"J. Psychoact. Drug."},{"issue":"10118","key":"10.1016\/j.psychres.2025.116446_bib0047","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.psychres.2025.116446_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120094","article-title":"Looking beyond the opioid receptor: a desperate need for new treatments for opioid use disorder","volume":"432","author":"Lee","year":"2022","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.psychres.2025.116446_bib0049","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/15563650.2016.1138226","article-title":"How toxic is ibogaine?","volume":"54","author":"Litjens","year":"2016","journal-title":"Clin. Toxicol."},{"issue":"34","key":"10.1016\/j.psychres.2025.116446_bib0050","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.15585\/mmwr.mm6934a1","article-title":"Nonfatal drug and polydrug overdoses treated in emergency departments - 29 states, 2018-2019","volume":"69","author":"Liu","year":"2020","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"issue":"3","key":"10.1016\/j.psychres.2025.116446_bib0051","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/02791072.2018.1447175","article-title":"Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing Ibogaine","volume":"50","author":"Malcolm","year":"2018","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.psychres.2025.116446_bib0052","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3389\/fphar.2018.00529","article-title":"Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes","volume":"9","author":"Mash","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.psychres.2025.116446_bib0053","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0099-9598(01)56012-5","article-title":"Ibogaine in the treatment of heroin withdrawal","volume":"56","author":"Mash","year":"2001","journal-title":"Alkaloid. Chem. Biol."},{"issue":"2","key":"10.1016\/j.psychres.2025.116446_bib0054","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neulet.2009.04.019","article-title":"18-Methoxycoronaridine blocks acquisition but enhances reinstatement of a cocaine place preference","volume":"458","author":"McCallum","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.psychres.2025.116446_bib0055","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","author":"McGuinness","year":"2020","journal-title":"Res. Synth. Method."},{"key":"10.1016\/j.psychres.2025.116446_bib0056","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fnbeh.2020.00075","article-title":"Ketamine blocks morphine-induced conditioned place preference and anxiety-like behaviors in mice","volume":"14","author":"McKendrick","year":"2020","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.psychres.2025.116446_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2023.107144","article-title":"Long-acting opioids and cardiovascular diseases: help or hindrance!","volume":"149","author":"Mehta","year":"2023","journal-title":"Vascul. Pharmacol."},{"issue":"2","key":"10.1016\/j.psychres.2025.116446_bib0058","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/2045125315626073","article-title":"Ibogaine-associated cardiac arrest and death: case report and review of the literature","volume":"6","author":"Meisner","year":"2016","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.psychres.2025.116446_bib0059","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/psymed.2023.0012","article-title":"Psilocybin for opioid use disorder in two adults stabilized on buprenorphine: a technical report on study modifications and preliminary findings","volume":"1","author":"Nicholas","year":"2023","journal-title":"Psychedel. Med."},{"issue":"1","key":"10.1016\/j.psychres.2025.116446_bib0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/00952990.2017.1310218","article-title":"Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study","volume":"44","author":"Noller","year":"2018","journal-title":"Am. J. Drug Alcohol. Abuse"},{"issue":"1","key":"10.1016\/j.psychres.2025.116446_bib0061","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jsat.2010.03.008","article-title":"Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996-2006","volume":"39","author":"Nosyk","year":"2010","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.psychres.2025.116446_bib0062","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.psychres.2025.116446_bib0063","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1037\/1064-1297.3.4.344","article-title":"Ibogaine attenuates morphine-induced conditioned place preference","volume":"3","author":"Parker","year":"1995","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.psychres.2025.116446_bib0064","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/0269881117691453","article-title":"The association of psychedelic use and opioid use disorders among illicit users in the United States","volume":"31","author":"Pisano","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2025.116446_bib0065","series-title":"Drug Overdose Deaths in the U.S. Top 100,000 Annually","author":"Prevention","year":"2021"},{"issue":"4","key":"10.1016\/j.psychres.2025.116446_bib0066","doi-asserted-by":"crossref","first-page":"A741","DOI":"10.1016\/j.chest.2022.08.583","article-title":"\"Spiritual awakening\u201d with Ibogaine instead awakens acute liver injury and rhabdomyolysis: a case report","volume":"162","author":"Ramanathan","year":"2022","journal-title":"CHEST"},{"key":"10.1016\/j.psychres.2025.116446_bib0067","series-title":"Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Treatment Guidance for Industry","year":"2020"},{"issue":"7","key":"10.1016\/j.psychres.2025.116446_bib0068","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00406-023-01590-1","article-title":"Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies","volume":"273","author":"Rocha","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.psychres.2025.116446_bib0069","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12012-016-9366-y","article-title":"Anti-addiction drug Ibogaine prolongs the action potential in Human induced pluripotent stem cell-derived cardiomyocytes","volume":"17","author":"Rubi","year":"2017","journal-title":"Cardiovasc. Toxicol."},{"issue":"6","key":"10.1016\/j.psychres.2025.116446_bib0070","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study","volume":"28","author":"Savage","year":"1973","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2025.116446_bib0071","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/0269881121991792","article-title":"First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder","volume":"35","author":"Sessa","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.psychres.2025.116446_bib0072","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1080\/02791072.2023.2190319","article-title":"Psychedelic treatments for substance use disorder and substance misuse: a mixed methods systematic review","volume":"55","author":"Sharma","year":"2023","journal-title":"J. Psychoact. Drug."},{"issue":"6","key":"10.1016\/j.psychres.2025.116446_bib0073","first-page":"176","article-title":"Lapse and relapse following inpatient treatment of opiate dependence","volume":"103","author":"Smyth","year":"2010","journal-title":"Ir. Med. J."},{"issue":"7","key":"10.1016\/j.psychres.2025.116446_bib0074","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamapsychiatry.2021.0259","article-title":"Moving beyond medications that act at the \u03bc receptor in the treatment of opioid use disorder","volume":"78","author":"Strain","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2025.116446_bib0075","doi-asserted-by":"crossref","first-page":"367","DOI":"10.5055\/jom.2018.0526","article-title":"Increases in body mass index and cardiovascular risk factors during methadone maintenance treatment","volume":"15","author":"Sweeney","year":"2019","journal-title":"J. Opioid. Manag."},{"issue":"1","key":"10.1016\/j.psychres.2025.116446_bib0076","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/15733998113099990003","article-title":"Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada","volume":"6","author":"Thomas","year":"2013","journal-title":"Curr. Drug Abuse. Rev."},{"issue":"9","key":"10.1016\/j.psychres.2025.116446_bib0077","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1111\/add.15818","article-title":"Clinical management of opioid withdrawal","volume":"117","author":"Torres-Lockhart","year":"2022","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.psychres.2025.116446_bib0078","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/ADM.0000000000001013","article-title":"Opioid use disorder treatment in the fentanyl era","volume":"17","author":"Varshneya","year":"2023","journal-title":"J. Addict. Med."},{"issue":"2","key":"10.1016\/j.psychres.2025.116446_bib0079","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/wps.20846","article-title":"The epidemic of fentanyl misuse and overdoses: challenges and strategies","volume":"20","author":"Volkow","year":"2021","journal-title":"World Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2025.116446_bib0080","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMsr1706626","article-title":"The role of science in addressing the opioid crisis","volume":"377","author":"Volkow","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.psychres.2025.116446_bib0081","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2023.1968","article-title":"Psychedelics as therapeutics-potential and challenges","author":"Volkow","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2025.116446_bib0082","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/02791072.2022.2133757","article-title":"Bibliometric analysis of academic journal articles reporting results of psychedelic clinical studies","volume":"55","author":"Weleff","year":"2023","journal-title":"J Psychoact. Drug."},{"issue":"6","key":"10.1016\/j.psychres.2025.116446_bib0083","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1007\/s43440-023-00539-4","article-title":"Cardiovascular safety of psychedelic medicine: current status and future directions","volume":"75","author":"Ws\u00f3\u0142","year":"2023","journal-title":"Pharmacol. Rep."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125000952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125000952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:40:26Z","timestamp":1777956026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178125000952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":83,"alternative-id":["S0165178125000952"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116446","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116446"}}